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What is already known about this subject:  
- The recent ABC and EMERGE guidelines provide recommendations on defining and 
reporting on adherence to medications but implementing these in research practice offers 
numerous challenges.  
What this study adds:  
- We propose TEOS, a framework for constructing operational definitions of medication 
adherence. 
- It outlines four components: Timelines, key Events, research Objectives and design, 
and available data Sources.  
- TEOS guides researchers to consider a broad range of questions regarding each 
component and record decisions and operational definitions explicitly. 
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Abstract 
Aim: Managing adherence to medications is a priority for health systems worldwide. 
Adherence research is accumulating, yet the quality of the evidence is reduced by various 
methodological limitations. In particular, the heterogeneity and low accuracy of adherence 
measures have been highlighted in many literature reviews. Recent consensus-based 
guidelines advise on best practices in defining adherence (ABC) and reporting of empirical 
studies (EMERGE). While these guidelines highlight the importance of operational 
definitions in adherence measurement; such definitions are rarely included in study reports. 
To support researchers in their measurement decisions, we developed a structured approach to 
formulate operational definitions of adherence.  
Methods: A group of adherence and research methodology experts used theoretical, 
methodological and practical considerations to examine the process of applying adherence 
definitions to various research settings, questions and data sources. Consensus was reached 
through iterative reviewing of discussion summaries and framework versions.  
Results: We introduce TEOS, a four-component framework to guide the operationalization of 
adherence concepts: 1) describe treatment as four simultaneous interdependent timelines 
(recommended and actual use, conditional on prescribing and dispensing); 2) locate four key 
events along these timelines to delimit the three ABC phases (first and last recommended use, 
first and last actual use); 3) revisit study objectives and design to finetune research questions 
and assess measurement validity and reliability needs, and 4) select data sources (e.g., 
electronic monitoring, self-report, electronic healthcare databases) that best address 
measurement needs. 
Conclusion: Using the TEOS framework when designing research and reporting explicitly on 




Research on medication adherence has developed substantially in recent years.1 It has produced 
to date important knowledge on adherence behaviours and their determinants 2,3, their 
relationship to health and economic outcomes4–7, and possible solutions to enhance adherence8. 
These findings show that suboptimal adherence is common and multidetermined, and that 
enhancing adherence is important for reducing the individual and societal burden of disease. 
However, evidence synthesis is constrained by considerable heterogeneity in study results; 
systematic reviews continue to highlight the low quality of measurement and high heterogeneity 
in adherence measures as one of the barriers for synthesizing results across studies.3,4,8–10 So far, 
various measures have been used in research and clinical practice, many with limited theoretical 
grounding and little or no validation.11 Important differences in estimates of adherence and its 
relationships with determinants and outcomes have been reported depending on the methods 
used for calculating adherence to the same medication, on identical or comparable populations 
and time periods.12–16 Improvement of adherence measurement is therefore a priority for the 
field. 
Several guidelines and recommendations have been proposed to improve the precision 
and standardization in adherence definitions and measurement. The consensus-based theoretical 
framework developed within the ABC (Ascertaining Barriers to Compliance) project17 provided 
conceptual definitions for adherence and terminology that have been widely adopted in 
adherence research. ABC distinguished between three phases: initiation (starting treatment), 
implementation (following the treatment as prescribed), and discontinuation (stopping 
treatment). It also highlighted the need to measure each independently and investigate specific 
causes and consequences for effective adherence management. Several literature reviews have 
proposed recommendations on adherence measurement and its three phases either by comparing 
different data sources11,18–20 or by reviewing alternative methods using the same type of data 
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source.16,21 They converge towards the view that there is no single, ‘gold standard’ measure for 
the overarching concept of medication adherence. Instead, optimal measurement needs to 
consider numerous theoretical, methodological and practical aspects and find a balance between 
generalizability and adaptation to the specific needs of individual studies. 
Guidelines for reporting adherence research have been proposed recently. For clinical 
trials, an outcome specification format has been suggested which requires information on four 
levels: domain, specific measurement, specific metric, and aggregation method.22 The 
EMERGE guidelines23 adapted this general format for adherence research and recommended 
four reporting criteria largely following the same process of specification from abstract to 
concrete: adherence phase(s), operational definitions, measurement methods including metric 
and statistical details, and summary results. However, while conceptual definitions and 
measures are commonly reported in empirical studies, operational definitions are rarely 
detailed. In this paper we propose practical recommendations we believe will facilitate the 
development and description of operational definitions. 
 
Methods 
Following the development of the EMERGE guidelines, an adherence methodology working 
group was convened, comprising of six experts in adherence measurement (each a member of 
ESPACOMP, four also members of the EMERGE steering committee). The working group 
collaborated between November 2016 and November 2019 to develop practical 
recommendations for operational definitions of medication adherence, consistent with 
components of good research practice, as part of a broader initiative to improve measurement 
and analysis standards in adherence research. Key theoretical and methodological bases were 
the ABC adherence taxonomy, the EMERGE guidelines and the three-step measurement 
process well-established in psychometric literature.24 The first step of this measurement process 
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– definition – identifies the attribute(s) to be measured and is represented in adherence research 
by the ABC taxonomy. The second step – operationalization – ascertains what needs to be done 
practically to know how the attribute(s) manifest(s) in a particular case; it thus translates the 
definition into a set of operations by which the previously defined attribute(s) will be observed 
in the study sample, and thus arrives at a more precise operational definition. The third step – 
quantification – translates operational definitions into numbers and thus allows data analysis 
and aggregation into summary measures. 
The group aimed to articulate general operationalization recommendations that would 
be consistent with the ABC and EMERGE principles and applicable to various types of 
medications, health conditions, healthcare systems, research designs, and data sources. By 
following this approach, researchers should be able to identify whether/how the ABC phases 
apply to their own study, and which measures are most appropriate for their needs. Group 
members used their experience in adherence research to assess critically the applicability of the 
principles proposed to various examples of adherence research. 
The study was funded by ESPACOMP, and group members co-authored this article. We 
present below the resulting recommendations with examples of research applications and 
discuss their implications and further developments necessary. 
 
Results 
The working group identified four main sources of variation that impact decisions concerning 
the measurement of adherence in clinical trials and routine clinical care. We present them in 
order of importance relative to defining adherence as a temporal sequence. First, treatment 
timelines may vary substantially for the same medication regimen, depending on prescribing, 
dispensing, dosing and usage practices. While these timelines may be more tightly controlled in 
clinical trials, treatment regimens become less standardized in clinical practice as they are 
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adapted to patients’ individual needs and preferences. Second, key events occurring on these 
timelines, such as starting and stopping medication, may vary between participants in clinical 
trials despite strict protocols, and even more so in routine care, where changing or reinitiating 
treatment may occur, either in agreement with the treating physician or independently. Third, 
studies may have various objectives, such as studying adherence predictors or consequences, 
accounting for the influence of non-adherence on drug exposure and efficacy, improving 
individuals’ adherence, or driving organization- or system-wide change. Depending on these 
objectives, the study design beyond adherence measurement may need adjustments depending 
on how related variables are placed in the temporal sequence described by adherence timelines 
and events. Fourth, various data sources may be available, with different limitations and 
possibilities, which may restrict how research questions are formulated and the type of evidence 
that can be generated about this temporal sequence. 
Due to these sources of variation, no single measure of adherence is appropriate in all 
situations. Instead, careful consideration of these domains would lead to selecting the most 
appropriate measure for each study. We therefore introduce TEOS (Timelines – Events – 
Objectives – Sources, Figure 1), a four-component iterative process that researchers can follow 
to include these considerations in adherence measurement and record decisions transparently. 
[insert Fig 1 here] 
The TEOS framework 
Timelines – what are the temporal characteristics of the medication regimen(s) under study?  
Adherence to medications is defined broadly as the process by which patients take their 
medications as prescribed. This implies comparing two timelines: recommended and actual 
dosing events. Moreover, as patients can only use medications if these are available to them, we 
also need to consider prescribing events and whether they are followed by dispensing events. 
Therefore, a first step is to understand conceptually how prescribed and actual use occurs in real 
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life for each medication in the study context and represent this information explicitly on four 
parallel timelines:  
1. Prescribing events: start dates and durations of prescriptions, 
2. Recommended dosing events (dosing regimen): quantity (e.g. two tablets) and frequency 
(e.g. twice daily) of the recommended sequence of dosing events during prescription 
intervals,  
3. Dispensing events: dates and durations of dispensations related to the specific 
prescriptions, which make medications available to patients, and  
4. Actual dosing events: date and time of administration of available medications. 
Figure 2 provides a representation of these timelines for one prescribed medication. They 
occur simultaneously during an observation window (OW; a period of interest for adherence 
estimation, e.g. a year, or a month), before or after a specific event (index date) in a follow-up 
window (FUW; a broader time period around the OW on which data relevant for adherence 
estimation may be available). The index date may be a clinical event, a consultation, or a first 
prescription of a specific medication after a period of no treatment. Mapping these timelines 
on each patient’s medication history is the first step towards accurate adherence measurement. 
[insert Fig 2 here] 
Key events – what are the boundaries delimiting adherence phases? 
The ABC taxonomy delimits the three adherence phases by four key events: (1) first 
recommended dosing event, (2) first actual dosing event (“initiation”), (3) last actual dosing 
event (“discontinuation”), and (4) last recommended dosing event. These four events are 
boundaries for all other prescribed and actual dosing events. Between a first and a last actual 
dosing event, the time-series of actual dosing events may correspond to a variable extent to the 
time-series of recommended dosing events; this variability is captured by the concept of 
“implementation”. In long-term care, patients may interrupt treatments multiple times for 
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extensive time periods covered by the same prescription; depending on the length of the FUW 
and OW, these periods of interruption may count towards low implementation or non-
persistence. At the same time, prescriptions may be stopped by a provider (event 4) and then 
restarted (event 1) at a later date. Identifying these events represents the second step in 
measuring adherence, as it allows the investigator to distinguish between the three adherence 
phases and subsequently identify suitable adherence metrics for each phase. Depending on the 
follow-up window length, the timelines may include one or more of the four key events, e.g. the 
probability of discontinuation increases with the duration the follow-up window. Understanding 
how the timing of these events varies is essential for deciding the timing of observation 
windows for adherence calculations within the same study, as well as for explaining 
inconsistencies in results between studies. 
Additional events may occur within an implementation phase, such as changes in 
recommended dosage and generic or therapeutic substitution which need particular 
consideration when assessing adherence outside controlled environments.25 These situations 
may be followed by a recommendation to finish the previous supply with the same or the new 
dosage regimen, or to discard any remaining medication and start the new prescription. Dose 
changes may also occur between prescription events, for example when prescribed regimens 
include recommendations to step up or down dosage depending on clinical need. These events 
may impact measurement, and therefore need to be recorded and considered in sample selection 
or adherence calculations. 
Research objectives and design – what adherence-related evidence we want? 
Operationalization is strongly related to research design, and the choice of adherence measures 
can impact relationships between predictors and outcomes.26 Understanding in depth the 
temporal characteristics of treatments and how we can delimit adherence phases will generate 
deeper insights into the adherence-related evidence we need and can generate, with new and 
 10 
perhaps unanticipated implications for research objectives and study design. We therefore 
recommend that researchers reflect on how the other variables they aim to measure in their 
study in relation to adherence (predictors, outcomes, mediators, moderators, potential 
confounders) are situated on the timelines described above. Without aiming to be 
comprehensive, we highlight here four examples of such considerations, which we explain 
below: 1) are these variables measured separately from adherence behaviors?; 2) do they change 
over time?; when do they occur or change and in what order relative to adherence timelines?; 
and 3) at what levels of analysis do they vary? For most studies, answering these questions 
would improve substantially the quality of the study design and the interpretation of results.  
Operational definitions of adherence require clear boundaries between the actual 
behavior, as per the ABC taxonomy, and other proximal variables. Irrespective of the adherence 
measure selected, valid causal inference between two measures requires that they are separate 
entities with little or no measurement overlap. For example, when examining relationships 
between adherence determinants and behaviors, researchers should avoid self-reported 
adherence scales that conflate questions on behaviors and determinants into single scores. Such 
scales are common in the literature.27 
Once conceptual boundaries are established, an analysis of the temporal properties of 
these variables would inform the timing of adherence measurement in relation to the study 
hypotheses. These variables may be time-invariant or time-varying properties, or single events. 
Their duration and how much they change in time should be considered when choosing the 
timing, frequency and duration of measurement for adherence, and the relevant adherence 
phases. Identifying the temporal sequence between adherence phase(s) and adherence-related 
variables is necessary for causal claims. For example, adherence would need to be measured 
after predictors and before outcomes, and the time lag between measurements should reflect 
causal effects that are biologically plausible.  
 11 
In thinking about adherence predictors and outcomes, it is important to note that 
healthcare systems are naturally hierarchical and causal influences can occur at multiple 
“levels.” Patients’ beliefs about health and healthcare, income, and access to health are 
examples of adherence predictors at the patient level which may remain stable during a study 
and thus amenable to investigation at between-person level. Other adherence predictors, such as 
symptom severity or emotional states, may vary and thus within-person causal effects can be 
studied. Healthcare professionals who prescribe and supply medicines may support or 
undermine medication adherence in a variety of ways, such as their interest and skill in 
collaborating with patients on medication taking, or the organizational infrastructure they 
establish for prescription refills or patient support. Similarly, some predictors are stable and be 
amenable to study at between-person level, while others may vary and thus allow the study of 
causal effects within-person, i.e. healthcare professional. Finally, there may be city, county, 
regional, or national-level factors affecting care. Both study questions and methods should 
reflect this multilevel nature of healthcare delivery28 and aim to detect and explain relevant 
variation at within- or between-patient level, healthcare professional, organization, or policy 
levels.29 The choice of analysis level(s) will depend on the practical applications envisaged, e.g. 
adherence indicators at practice level are less useful for intervention at patient level, but could 
be a target of healthcare professional behavior change.30 It will result in different temporal 
dynamics to be captured, as some phenomena may have higher temporal variation within-
patient and more stability at policy level. For example, if we aim to produce evidence for 
managing adherence in provider-patient consultations, we might focus on individual-level 
implementation patterns or persistence measures and a short- to medium timeframe. 
Alternatively, if we are interested in organization-level or system-wide diagnosis and change, 
we might examine population-level initiation and persistence distributions. The limited 
awareness of the importance of levels of analysis in adherence research so far is detrimental to 
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the field, as evidence produced at one level is often interpreted at another.31 We therefore 
encourage researchers to perform this mapping exercise explicitly and refine research objectives 
in light of these considerations. 
Data sources – what is accessible? 
In order to match what we want to know with what we can know in specific settings, 
operational definitions need to consider the possibilities and limitations of available data 
sources in relation to the evidence required, which in essence is the temporal sequence of actual 
versus prescribed dosing and its place within the broader causal process involving the treatment 
regimen. The most common data sources in adherence research are electronic healthcare 
databases (e.g. electronic health records, claims, record linkage systems),32 electronic 
monitoring devices, and self-reports. Advantages of different data sources and measures have 
been discussed elsewhere in relation to adherence stages.11,18,19 
To maximize data quality, it is essential to evaluate several data sources potentially 
available for research with respect to quality dimensions specific to each source (e.g. reliability, 
validity, responsiveness, and interpretability for self-report).33 This evaluation needs to be 
performed in relation to the adherence phase(s) and research objectives targeted. A single data 
source may contain information about one or multiple timelines and therefore makes it possible 
to compute markers for one or more adherence phase(s). Examples include: a dated note in an 
electronic health record indicating that a prescription was written; a medication plan detailing 
the prescribed regimen; a date in an administrative dataset showing that a prescription was 
filled; a smart (electronic) package opening event with date and time; a self-reported statement 
of no missing dose in the previous week; and a dated note in a health record that a medication 
was re-prescribed after a 6-month gap. Alternatively, combining multiple data sources may 
reduce bias and measurement error by aggregating complementary information on different 
 13 
timelines and events to generate a comprehensive data set and check consistency, e.g. in 
composite measures34 or by linking prescribing and dispensing data.35 
These four types of information – timelines, events, objectives, and sources – are 
necessary to describe the events required to measure adherence according to the ABC 
taxonomy, and the temporal dynamics of the relationships of interest. Sometimes all the desired 
information is directly available, but more often we can only approximate the theoretical time 
series of prescribed and actual dosing events. For example, we infer from a first dispensing 
event that someone started a treatment (initiation), from a smart package opening event that 
someone took a dose (implementation), or from a certain gap between refill events that 
medication taking has been discontinued (persistence). 
Using the framework 
We therefore propose to consider, when constructing operational definitions of adherence, a 
series of questions addressing the four TEOS components (Table 1). The question order in 
Table 1 highlights the importance of adherence timelines as described above, but the process 
we propose is by no means linear. As TEOS components interact, the order in which the 
questions are tackled in a specific study may vary and decisions in one component may 
require adjustments in another. For example, decisions related to data sources following 
quality evaluation may induce changes to study design features, such as inclusion criteria and 
measurement of other variables. Answering these questions might prove straightforward in 
some contexts, for example if the study population is homogeneous and information is easily 
available, while in others more research might be necessary to support operationalization 
choices, such as method validation or sensitivity analyses. Nevertheless, we believe that these 
questions would help researchers make informed choices on operational definitions of 
adherence. 
[insert Table 1 here] 
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After this exercise, operational definitions can be formulated for all relevant adherence 
measures consistent with the ABC taxonomy. We provide an example for reporting the TEOS 
exercise in tabular form (Table 2) and as graphical representation (Figure 2) for an 
intervention study to support medication adherence for patients starting any new chronic 
treatment. The operational definitions for each adherence phase are provided in Box 1, 
together with possible quantification and summary measures. Two additional examples are 
presented in Appendix 1. 
[insert Table 2 here] 
[insert Figure 3 here] 
 
Discussion 
A solid evidence base for adherence to medications requires shared standards and definitions, 
for which the ABC taxonomy and EMERGE guidelines have set the foundation. Applying 
them in practice requires shared procedures for understanding and measuring adherence 
processes in various clinical settings.36 We propose TEOS, a four-component framework that 
researchers may use to perform a conceptual analysis of adherence timelines and key events in 
relation to research objectives and data sources. By using TEOS, we hope to encourage 
researchers to explore more options for study design and identify more accurate ways to 
measure adherence, formulate hypotheses and analyze data. Although full replication and 
cross-study comparability will always be difficult to achieve as rarely two studies will share 
the same specifics, we believe that reporting operational definitions using TEOS will improve 
transparency and reproducibility of adherence studies and thus facilitate comparisons. 
TEOS highlights the fact that many important research questions regarding medication 
adherence are not being asked with sufficient rigor. Prior reviews have noted that initiation 
and persistence are less studied than implementation,9 and adherence has been studied more at 
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patient level than at the provider or health care site levels.29 Moreover, TEOS points to 
several key limitations in previous studies regarding the temporal properties of adherence and 
its multilevel variation.28 Not separating adherence phases is common, and a source of 
measurement error and confusion in interpreting results.37 Current interventions targeting 
changes in adherence within-person rely mostly on evidence at the between-person level, 
which may be subject to different influences; distinguishing between- and within-person 
variation in adherence holds promise for improving adherence interventions.31 We hope that 
the explicit use of TEOS will stimulate new research in these less explored areas, and result in 
the formulation of more precise hypotheses which can generate more actionable evidence for 
adherence management. 
The TEOS framework focuses on operationalization of medication adherence and 
design of research involving this construct and is intended to stimulate debate and promote 
consensus among the research community. The format of the examples we give of operational 
definitions represents an initial proposal for discussion. We intentionally did not review or 
endorse specific adherence measures or approaches to quantification or aggregation, as their 
appropriateness depends on the interactions between the four components we illustrated here 
and the relevance of the different choices to specific settings. Several options for summarizing 
adherence across values (e.g. median implementation percentage) or across patients (e.g. 
percentage of patients implementing as prescribed over a specific threshold value) have been 
proposed and raise various analysis challenges38 which are beyond the scope of this article. 
Guidance on how to operationalize clinical outcomes in relation to adherence is also beyond 
its scope; TEOS needs to be used in combination with other guidelines relevant for the type of 
study conducted.  
TEOS is described here for a single medication, yet long-term treatments typically 
involve multiple medications (polypharmacy), often aiming for non-additive effects.39,40 
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Adherence timelines may differ substantially between medications, resulting in potential 
overlapping intervals of initiation, persistence/implementation, and non-persistence for different 
medications. In certain cases, it might be useful to consider adherence to a treatment consisting 
of multiple medications instead of single medications.41,42 Treatment effects of some 
medications are importantly affected by the concomitant/sequential use of other medications, or 
other substances, such as food, etc., which may need to be taken into account in how adherence 
to polypharmacy is operationalised; these other events may represent additional layers of 
information to consider in adherence studies. Operational definitions of polypharmacy could 
build on the TEOS framework and add questions specific to multiple medication regimens. 
The ESPACOMP adherence methodology working group aims to provide the research 
community with practical tools for developing a high-quality evidence base for adherence 
management decisions from individual to policy level. TEOS is part of this objective, as well as 
of the broader movement towards transparency and reproducibility in research. Its application to 
different medication regimens and clinical settings would advance our understanding of 
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Table 1: Examples of questions to consider for each TEOS dimension. 
TEOS 
Dimension 
Examples of questions to consider for each prescribed/recommended 
medicine in the research setting 
Timelines 1. Prescribing events:  
1. When are the prescriptions issued? 
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2. How long are they valid for? 
3. When are they renewed?  
2. Recommended dosing events:  
1. When is dosing expected to begin after prescription? 
2. Are doses and dosing intervals (frequency of administration) fixed or 
do they vary within patients, between patients or at other levels? If 
they vary, what is the range of values? 
3. Do medication effects depend on additional recommendations? (e.g. 
inhaler technique, administer with food, etc.) 
3. Dispensing events: 
1. For how many days are medications supplied? 
2. What is the expected refill frequency? 
3. Does automatic dispensing occur? 
4. Actual dosing events:  
1. What are the administration routes? 
2. How can patients modify medications (e.g. tablet splitting)? 
3. If additional recommendations apply (e.g. with food), are these 
followed when administering? 
Events General questions in relation to all events: 
1. When does the follow-up window (time for which data are available) 
start and end? 
2. When does the observation window (time for which adherence is 
measured) start and end? 
Specific questions about particular events 
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1. First recommended dosing event: What minimum duration without 
prescribed use should precede a first recommended dosing event so 
that this event can be considered the start of a new treatment? 
2. Last recommended dosing event:  
1. How is the date of treatment end identified?  
2. How is treatment end differentiated from treatment 
switching (e.g. brand versus generic, single versus 
combination drugs)? 
3. First actual dosing event: What is the maximum duration between 
first recommended dosing event and first actual dosing event 
before non-initiation is assumed?   
4. Last actual dosing event:  
1. What is the minimum duration with no actual dosing events 
to differentiate between poor implementation and non-
persistence? 
2. How is discontinuation differentiated from treatment 
switching? 
Objectives Intervention: What intervention(s) will be provided with a potential 
impact on medication adherence?  
Predictors: What potential predictors of adherence will be measured 
and/or targeted by the intervention(s)?  
Outcomes: What outcomes will be measured? How are they affected by 
medication adherence?  
Moderators/mediators: What variables will be measured? How do they 
intervene in the causal process?  
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General questions in relation to all variables: 
1. Are they measured separately from adherence behaviors? 
2. Do they change in time (i.e., time-varying)? 
3. What is the temporal sequencing in relation to adherence? 
4. At what levels of analysis do they vary? (within- or between-patients, 
healthcare professionals, etc.) 
Sources 1. What data sources are available to derive the four 4 key events? 
2. What additional data are available to measure adherence? 
3. For what time period(s) are data available? 
4. How complete are the available datasets? 
5. What is the validity/reliability of the available data? 
6. What are the options for additional data collection? 





Table 2: TEOS for an intervention study to support medication adherence for patients starting 
any new chronic treatment. The intervention will be provided in cluster-randomized 
pharmacies within 6 weeks after the first dispensing event and consist of 2 interviews, the first 
until up to 3 weeks, and the last at 4-6 weeks after the start of the treatment. We want to 





Prescription events: one first prescription issued, typically for 30 days 
(duration D1), that can be filled 1 time and is followed by subsequent 
prescriptions for long-term use (6+ months, D2) 
Recommended dosing events: treatments will be prescribed to start 
immediately, for regular use (e.g. daily to weekly, dosing varies; ‘as needed’ 
use is excluded),  
Dispensing events: the first dispensing event can happen within 30 days 
after the first prescription and covers up to 30 days (D3). Subsequent 
dispensing events may cover up to 90 days (D4). Automatic dispensing does 
not occur. 
Actual dosing events: patients are expected to self-administer their 
medication, the mode of administration varies, any type of modification is 
possible (e.g. reducing/increasing doses, skipping/delaying administration; 
seasonal variability may play a role for some medications and needs to be 





First recommended dosing event: date of first prescription (time T0) after a 
1-year baseline period with no prescriptions for the same substance – it 
represents the start of the observation window (OW, T0) 
Last recommended dosing event: date of prescription discontinuation (if 
within the OW), or after the end of the OW (T2) 
First actual dosing event: occurs after first dispensation (T1), date may vary 
but most participants are likely to initiate before the first interview which 
takes place up to 3 weeks after first dispensation.  
Last actual dosing event: possibly occurring anytime during the OW if 




The intervention will be initiated at the first dispensing event in the 
pharmacy. We are interested in the short-term effects of this intervention on 
patients’ adherence, compared to a control group receiving usual care. We 
want to measure the impact of the intervention on initiation, implementation 
and persistence in the first 10 weeks after the first dispensing event.  
We also aim to investigate the correlation between occurrence of side 
effects and adherence at 10 weeks. 
Cluster randomization will occur at pharmacy level. Several patient-level 
time-invariant (non-modifiable) characteristics will be controlled for. Health 




We can collect participants’ self-reports of behavior and side effect 
occurrence (standardized battery of items during the intervention). We also 
have access to pharmacy refill dates and quantities (electronic records of 
actual dispensing events) and prescription dates (manually entered by 
pharmacy staff), but only for medications dispensed in the pharmacy 
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providing the first dispensation. Recommended dosages are not easily 
accessible in routine data but could be obtained from patients or healthcare 
professionals. Electronic monitoring is not feasible due to logistics, mainly 





Box 1: Operational definitions for measuring adherence in the example study 
Initiation:  
Patients with at least one refill recorded within 10 weeks after the first dispensing event and 
who self-reported at least one actual dosing event within 10 weeks (data extracted from 
patient record).  
Quantification: Binary variable (yes/no).  
Summary measure: percentage initiating patients 
Persistence:  
Patients who initiated treatment, have no documented end of recommended use and self-
reported at least one actual dosing event in week 10 (data extracted from patient record).  
Quantification: Binary variable (yes/no).  
Summary measure: percentage persistent patients 
Implementation: Self-reported quality of implementation by patients who were persistent at 
week 10, as measured by the Three-Item Self-Report Measure for Medication Adherence at 
week 10.44  
Quantification: Continuous variable as per scoring instructions (percentage, range 0 – 100).  















• first recommended 
• first actual dosing
• last recommended









Figure 2: Four timelines of medication adherence: Prescribed use with prescriptions and 
recommended dosing events and Actual use with dispensations and actual dosing events. 




Figure 3: Example for a graphical representation of the TEOS exercise. D1-D4 and T0-T3 
refer to the timelines and events, respectively, mentioned in Table 2 above. Dashed 
rectangles: Follow-up window (black) and observation window (green). The intervention 
(orange line) is provided by healthcare professionals to patients and consists of two 
interviews which occur at up until 3 weeks and 4-6 weeks after intervention start; self-
reported adherence data are collected at these times (orange diamonds). Additional 
predictors and outcomes are measured at the patient level (grey lozenge). 
